Insider filing
Traded Oct 8 · filed 37 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
NSRX · NYSE American · Pharmaceutical Preparations · Foreign private issuer
Nasus Pharma (NSRX) · oqro.io/stocks/NSRX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.66−0.21 (−7.32%)
Close of Nov 16, 2026, vs Nov 13 · end-of-day, not a live quote
Including 1 routine filing (option exercises, tax withholding, grants, gifts). Open-market trades only
Insider filing
Traded Oct 8 · filed 37 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider buying
Traded Jun 17 · filed 5 days later
Since the trade −13.6% · S&P 500 −0.1% · to Nov 16
The CEO of Nasus Pharma paid $20K out of pocket for Nasus Pharma shares.
Insider buying
Traded Apr 22 · filed 1 day later
Since the trade −31.6% · S&P 500 +4.0% · to Nov 16
The CEO of Nasus Pharma paid $11K out of pocket for Nasus Pharma shares.
Insider buying
Traded Mar 31 · filed 1 day later
Since the trade +19.8% · S&P 500 +13.8% · to Nov 16
The CEO of Nasus Pharma paid $31K out of pocket for Nasus Pharma shares. Shares held went up 240% with this purchase.
No earnings release (8-K Item 2.02) is on file for NSRX, so its insider trades cannot be placed against one.